1. |
Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2017. Bethesda: National Cancer Institute. 2019(2019-11)[2020-04]. https://seer.cancer.gov/archive/csr/1975_2017/index.html.
|
2. |
Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc, 1946, 132(14): 838-847.
|
3. |
Ciarallo A, Rivera J. Radioactive iodine therapy in differentiated thyroid cancer: 2020 update. AJR Am J Roentgenol, 2020, 215(2): 285-291.
|
4. |
Jacobs D, Breen CT, Pucar D, et al. Changes in population-level and institutional-level prescribing habits of radioiodine therapy for papillary thyroid cancer. Thyroid, 2021, 31(2): 272-279.
|
5. |
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016, 26(1): 1-133.
|
6. |
Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging, 2008, 35(10): 1941-1959.
|
7. |
林巖松, 張騰. 放射性碘治療局部進展期分化型甲狀腺癌的價值. 中國實用外科雜志, 2023, 43(8): 876-881.
|
8. |
Su J, Gao G, Xu H. Bibliometric analysis of research on thyroid ultrasonography. Gland Surg, 2021, 10(12): 3283-3293.
|
9. |
Song B, Lin Z, Feng C, et al. Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis. Front Endocrinol (Lausanne), 2023, 14: 1252389. doi: 10.3389/fendo.2023.1252389.
|
10. |
Falagas ME, Pitsouni EI, Malietzis GA, et al. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J, 2008, 22(2): 338-342.
|
11. |
van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics, 2010, 84(2): 523-538.
|
12. |
Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol, 2022, 10(4): 264-272.
|
13. |
Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab, 2019, 104(9): 4087-4100.
|
14. |
Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid, 2019, 29(4): 461-470.
|
15. |
Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth edition): what changed and why?. Thyroid, 2017, 27(6): 751-756.
|
16. |
Sun YQ, Sun D, Zhang X, et al. Radioiodine adjuvant therapy in differentiated thyroid cancer: an update and reconsideration. Front Endocrinol (Lausanne), 2022, 13: 994288. doi: 10.3389/fendo.2022.994288.
|
17. |
林巖松. 分化型甲狀腺癌的碘-131治療現狀和進展. 中華耳鼻咽喉頭頸外科雜志, 2019, 54(1): 62-68.
|
18. |
林巖松. 有關放射性碘難治性分化型甲狀腺癌靶向治療的思考與初探. 中華核醫學與分子影像雜志, 2023, 43(8): 449-451.
|
19. |
Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, 2014, 384(9940): 319-328.
|
20. |
Zhang X, Zhang F, Li Q, et al. The relationship between urinary iodine concentration and papillary thyroid cancer: a systematic review and meta-analysis. Front Endocrinol (Lausanne), 2022, 13: 1049423. doi: 10.3389/fendo.2022.1049423.
|
21. |
鄭榮壽, 孫可欣, 張思維, 等. 2015 年中國惡性腫瘤流行情況分析. 中華腫瘤雜志, 2019, 41(1): 19-28.
|
22. |
Piccardo A, Puntoni M, Bottoni G, et al. Differentiated thyroid cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy. Eur J Nucl Med Mol Imaging, 2017, 44(6): 926-934.
|
23. |
中國臨床腫瘤學會(CSCO)甲狀腺癌專家委員會, 中國研究型醫院學會甲狀腺疾病專業委員會, 中國醫師協會外科醫師分會甲狀腺外科醫師委員會, 等. 碘難治性分化型甲狀腺癌的診治管理共識(2019年版). 中國癌癥雜志, 2019, 29(6): 476-480.
|
24. |
張騰, 宋麗萍, 趙騰, 等. 淋巴結轉移對分化型甲狀腺癌手術及131I治療后血清甲狀腺球蛋白抗體轉陰的影響. 中國醫學科學院學報, 2017, 39(4): 539-543.
|
25. |
Giovanella L, Avram AM, Clerc J, et al. Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?. Eur J Nucl Med Mol Imaging, 2018, 45(12): 2155-2158.
|
26. |
Jayasekara J, Jonker P, Lin JF, et al. Early postoperative stimulated serum thyroglobulin quantifies risk of recurrence in papillary thyroid cancer. Surgery, 2020, 167(1): 40-45.
|
27. |
Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med, 2012, 366(18): 1663-1673.
|
28. |
Lin YS, Yang H, Li XY, et al. Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer-phase Ⅰ/Ⅱ study. Eur J Nucl Med Mol Imaging, 2022, 49(12): 4171-4181.
|
29. |
中國臨床腫瘤學會甲狀腺癌專業委員會, 中國研究型醫院學會分子診斷專業委員會甲狀腺癌學組, 醫促會甲狀腺疾病專業委員會核醫學組, 等. 分化型甲狀腺癌術后131I治療前評估專家共識. 中國癌癥雜志, 2019, 29(10): 832-840.
|
30. |
鄭斌, 高峰, 韓若凌. 甲狀腺結節超聲惡性風險評估相關國內外指南的對比與解讀. 河北醫科大學學報, 2019, 40(8): 872-876.
|
31. |
馬靜, 崔立剛, 王淑敏. 甲狀腺乳頭狀癌侵襲性亞型病理分子生物學特征的研究進展. 中華醫學超聲雜志(電子版), 2021, 18(4): 412-415.
|
32. |
Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA, 2013, 309(14): 1493-1501.
|
33. |
Thies ED, Tanase K, Maeder U, et al. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging, 2014, 41(12): 2281-2290.
|
34. |
劉杰蕊, 張鑫, 孫郁青, 等. BRAFV600E突變輔助預測放射性碘難治性分化型甲狀腺癌阿帕替尼治療效果的意義. 中華核醫學與分子影像雜志, 2023, 43(8): 465-469.
|
35. |
Shen J, Shen H, Ke L, et al. Knowledge mapping of immunotherapy for hepatocellular carcinoma: a bibliometric study. Front Immunol, 2022, 13: 815575. doi: 10.3389/fimmu.2022.815575.
|
36. |
何林燁, 王藝超, 李志輝. 2022年中國甲狀腺癌流行情況分析: 基于《中國腫瘤登記年報》2005–2018年數據. 中國普外基礎與臨床雜志, 2024, 31(7): 790-795.
|